ClinicalTrials.gg
CompletedNCT01295619Updated Nov 28, 2016

Performance and Safety of I-020805 in Prevention of Cerebrospinal Fluid (CSF) Leakage Following Elective Craniotomy

An interventional study of I-020805 in Cerebrospinal Fluid Leakage, sponsored by Kuros Biosurgery AG. Completed at 4 sites in 2 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2016-11-28.

Sponsored by Kuros Biosurgery AG · Not applicable, Interventional, and Prevention

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
41
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Study summary

This is a prospective study to evaluate the performance and safety of a new medical device used in case of cerebrospinal fluid (CSF) leakage after an elective cranial surgery.

Read the detailed description

Patients who consented to participate in the trial and fulfilled the preoperative inclusion and exclusion criteria underwent screening prior to surgical treatment. After dural suturing, if patients met the intra operative inclusion and exclusion criteria, they received I-020805. If necessary, autologous grafts were to be used to augment dural closure.

I-020805 was delivered from a double syringe applicator that creates a fine layer over the dura. This layer quickly sets within seconds to form a watertight seal.

02

Conditions studied

  • Cerebrospinal Fluid Leakage

Keywords

  • Dura
  • Sealant
  • Cranial
  • Craniotomy
  • CSF leakage
  • CSF leakage following cranial surgery
03

In context

Cerebrospinal Fluid Leak

41 studies on the registry are indexed under Cerebrospinal Fluid Leak; 9 are open to participants now.

This study's enrollment of 41 is below the median of 74 across 24 interventional studies indexed under Cerebrospinal Fluid Leak.

Browse Cerebrospinal Fluid Leak studies →

Lead sponsor

Kuros Biosurgery AG is the lead sponsor of 12 studies on the registry; 2 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

Pre-operative

  • Male or female of 18 years old or over
  • Elective cranial procedure entailing a dural incision of at least 2 cm in length
  • Requires a procedure involving surgical wound classification Class I/Clean
  • Signed form
  • Negative pregnancy test at screening for women of and agreeing to use an acceptable method or abstinence until 90 days post-surgery

Intra-operative

  • Surgical wound classification Class I/Clean
  • Dural margin from bony edges of at least 3 mm throughout
  • Spontaneous expression of CSF assessed visually or a CSF leakage upon Valsalva maneuver

Exclusion criteria

Exclusion Criteria:

Pre-operative

  • Cranial procedure requiring translabyrinthine, transoral and/or any procedure penetrating the air sinus or mastoid air cells
  • Presence of symptomatic hydrocephalus
  • Pre-existing external ventricular drainage or lumbar CSF drain
  • Radiotherapy in the planned surgical region which ended within 3 months prior to planned surgery
  • Presence of systemic infection
  • Known history of hemophilia or other coagulopathy
  • Known oral anticoagulant use
  • Pregnancy or breast feeding
  • Known allergy to any components of I-020805
  • Previous participation in this trial or any drug or device study within 30 day of screening
  • Known clinically significant organ or systemic diseases
  • Known or suspected non-compliance with trial procedures

Intra-operative

  • Patient not meeting the pre-operative eligibility criteria
  • Not able to tolerate a Valsalva maneuver
  • Gap of more than 2 mm remaining after primary closure of dura
  • Use of synthetic or non-autologous duraplasty material
Terms in these criteria, in plain language(5)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Not applicable
Primary purpose
Prevention
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
41 participants (actual)

Study arms

  • Experimental
    I-020805

    This was a prospective, open, multi-center, single-arm study to investigate I-020805 in patients following elective cranial surgery. If they met the inclusion/ exclusion criteria, they receive I-020805 after suturing of the dura. If necessary, autologous grafts were to be used to augment dural closure.

    Device: I-020805

Interventions

  • DeviceI-020805

    A thin layer of I-020805 applied up to two times on the sutured dura mater

06

What researchers measure

Primary outcomes

  1. Performance of I-020805 in prevention of CSF leakage

    Time frame: Intraoperative on the day of sugery

Secondary outcomes

  1. Incidence of CSF leakage

    Time frame: Within 7 days after surgery or prior to discharge

  2. CSF leakage or pseudomeningocele related surgical intervention

    Time frame: Within 90 days following surgery

  3. CSF leakage confirmed by clinical evaluation or diagnostic testing

    Time frame: Within 90 days following surgery

  4. Surgical infection and unexpected neurological signs

    Time frame: Post-operative and within 7 days and 90 following surgery

  5. Wound healing impairment

    Time frame: Throughout study up to 90 days following surgery

  6. Incidence of all and treatment emergent adverse events

    Time frame: Throughout study up to 90 days following surgery

07

Study locations

4 sites
  • Charite Universitätsmedizin (01)
    Berlin, 13353, Germany
  • Orszagos Idegtudomanyi Intezet (11)
    Budapest, 1145, Hungary
  • Debreceni Tudomanyegyetem (12)
    Debrecen, 4023, Hungary
  • Szegedi Tudomanyegyetem (10)
    Szeged, 6725, Hungary
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Feb 2011, a primary completion of Dec 2011 and a completion of Dec 2011. It does not say whether these dates are actual or estimated.

How these figures are worked out, and which studies are left out of them.

Registered
Feb 9, 2011
First posted
Feb 14, 2011
Start
Feb 2011
Primary completionActual
Dec 2011
CompletionActual
Dec 2011
Last update
Nov 28, 2016
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Nov 28, 2016, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT01295619
Lead sponsor
Kuros Biosurgery AG
Responsible party
Sponsor
First posted
Feb 14, 2011
Start date
Feb 2011
Primary completion
Dec 2011
Completion
Dec 2011
Last update
Nov 28, 2016

Study contacts

Virginia Jamieson, MD
study director · Kuros Biosurgery

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Nov 2016. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion